A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.
Latest Information Update: 09 Dec 2018
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
- 13 Nov 2018 Results reporting the 3-year Post Treatment efficacy presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 24 Oct 2017 Results (n=282) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 28 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.